Sanofi strengthens vaccines manufacturing capacity in Singapore
The company will invest €400 million in a new site to enable it to produce vaccines on a massive scale for Asia
Building on last month's announcement of its plan to construct a new facility in Canada to increase its global availability of high-dose flu vaccines, Sanofi has now said it is also investing €400 million to create a unique vaccine production centre in Singapore.
The five-year project is currently entering its design phase with construction expected to begin in Q3 2021, with the site expected to be fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed.
Sanofi said the facility will "push the boundaries of operation through cutting-edge manufacturing and digital technologies."
"By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur.
The factory will be designed around a central unit housing several fully digitalized modules allowing production of three to four vaccines simultaneously, versus only one in current industrial sites.
It will also be able to leverage multiple vaccine manufacturing technology platforms based on different cell types, allowing the production of a specific vaccine to be prioritized in a faster timeframe depending on public health needs, Sanofi said.
Dr Beh Swan Gin, Chairman of the Singapore Economic Development Board said Sanofi’s decision to locate its first-in-Asia digitally-enabled vaccine production center in Singapore "is an endorsement of Singapore’s position as a leading centre for advanced manufacturing."
The project is expected to create up to 200 local jobs and enhance Singapore’s position as a regional innovation hub for the healthcare industry.
Last month, Sanofi announced it would invest more than €600 million to build a vaccine manufacturing facility at its existing site in Toronto to provide additional antigen and filling capacity for its Fluzone influenza vaccine for the Canadian, US and European markets.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance